Orgenesis Inc Stock Price, News & Analysis

Orgenesis reported a 96% increase in revenue for 2020, totaling $7.7 million. The company anticipates it will more than double its revenue in 2021 based on existing contracts. Following the strategic sale of its Masthercell division for $315 million, Orgenesis is focused on expanding its POCare platform, aimed at reducing costs and improving access to cell and gene therapies. The company has developed over 30 therapies and established partnerships in 14 countries to provide decentralized treatment solutions. A conference call to discuss these results is scheduled for March 9, 2021.

Orgenesis (NASDAQ: ORGS) has entered a collaboration agreement with Dong-a University Hospital and Cure Therapeutics to leverage its Mobile Processing Units and Labs (OMPULs) for the development of cell and gene therapies. This initiative aims to enhance regulatory compliance and accelerate commercialization of immunotherapies for cancer and infectious diseases. The partnership follows a joint venture agreement focusing on a therapeutic pipeline across South Korea and Japan, aiming to improve manufacturing quality and reduce costs, thereby supporting Orgenesis's mission to provide affordable and accessible CGTs.

Orgenesis Inc (NASDAQ: ORGS) announced plans for a conference call on March 9, 2021, to discuss its financial results for the 2020 fiscal year, ended December 31, 2020. The call will cover corporate progress and developments.

U.S. callers can join by dialing 877-545-0320, and international callers can use +1 973-528-0016, using entry code 796258. A webcast will be available at the company's Investor Events section. A replay will be accessible until March 23, 2021.

Orgenesis Inc. (NASDAQ: ORGS) announced its participation in the Winter Wonderland Conference hosted by The MicroCap Rodeo from February 16-19, 2021. CEO Vered Caplan is scheduled to present on February 16 at 2:30 PM Eastern Time, with a live webcast available. The conference features top investment ideas with one-on-one meetings for institutional investors on February 18-19. Orgenesis focuses on developing affordable cell and gene therapies through its POCare Platform, enabling scalable production at the point of care.

Orgenesis (NASDAQ: ORGS) reports a significant 40% revenue increase to $1.7 million in Q3 2020, up from $1.2 million in Q3 2019. Cash and cash equivalents stand at approximately $88.8 million as of September 30, 2020. The company continues to enhance its POCare strategy, expanding its therapeutic pipeline through the acquisition of Koligo Therapeutics. Upcoming projects include clinical trials for KT-PC-301, targeting COVID-19-related Acute Respiratory Distress Syndrome, and KYSLECEL, available for pancreatitis. Orgenesis also plans to roll out new automated cell therapy processing units globally.

Orgenesis (NASDAQ: ORGS) has announced that its 2020 Annual Meeting will be held virtually on November 18, 2020, due to the public health impact of COVID-19. Stockholders of record as of September 21, 2020, can attend the meeting via a provided link and control number. Pre-voting is encouraged, and proxy materials will not be updated to reflect the virtual format. Digital copies of the proxy statement and 2019 Annual Report are available on the company's website. This decision aims to prioritize stockholder health and well-being amidst ongoing pandemic challenges.

Orgenesis Inc (NASDAQ: ORGS) announced the completion of its acquisition of Koligo Therapeutics, Inc. and substantially all assets of Tissue Genesis, LLC, enhancing its POCare technology resources. The Icellator®, a point-of-care device for cell isolation, is now commercially available in Korea and the Bahamas, with plans for expansion into Japan by Q1 2021. The company aims to leverage these assets for developing affordable autologous cell therapies. The Koligo acquisition was valued at approximately $14.5 million in shares and included liabilities of $1.9 million.

Orgenesis Inc. (NASDAQ: ORGS) has signed a Services Agreement with Therapeutics, Inc. to develop its Ranpirnase topical formulation aimed at treating external genital warts caused by HPV. This collaboration precedes an investigational new drug submission and will explore enhanced targeting using Orgenesis’ Bioxomes™ technology. A Phase 2 study is planned for early 2021, building on promising Phase 1/2 results where Ranpirnase demonstrated safety and efficacy. EGW represents a significant health concern with around 400,000 new cases annually in the U.S.

Orgenesis Inc (NASDAQ: ORGS) provided a business update for Q2 2020, reporting a 55% revenue increase to $1.7 million from $1.1 million in Q2 2019. As of June 30, 2020, the company has $97.5 million in cash. Key advancements include collaborations for validating POCare Technologies and the launch of the BioShield Program to tackle viral pathogens like COVID-19. Orgenesis is advancing its cell-based vaccine platform and engaging in partnerships for treatments related to COVID-19, showcasing its commitment to innovative therapies at the point of care.